Clear Street raised the firm’s price target on Trevi Therapeutics (TRVI) to $29 from $21 and keeps a Buy rating on the shares. The company’s key opinion leader event has strengthened the firm’s conviction in Haduvio’s potential to address the chronic-cough market, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRVI:
- Trevi Therapeutics price target raised to $20 from $18 at Morgan Stanley
- Trevi Therapeutics Charts Cash-Rich Path Through Key Trials
- Analyst Reiterates Buy on Trevi Therapeutics, Slightly Lowers Price Target to $23 Amid Advancing Haduvio Pipeline
- Unusually active option classes on open April 17th
- Trevi Therapeutics Prices Public Offering to Fund Haduvio